Lind Global Fund III LP and Affiliates File Schedule 13G for Silexion Therapeutics Corp

Lind Global Fund III LP, Lind Global Partners III LLC, and Jeff Easton have filed a Schedule 13G with the SEC, disclosing their beneficial ownership of 224,050 ordinary shares of Silexion Therapeutics Corp, representing 9.9% of the company's outstanding shares. The filing includes details of the ownership structure, with Lind Global Partners III LLC, the general partner of Lind Global Fund III LP, and Jeff Easton, the managing member of Lind Global Partners III LLC, each having sole voting and dispositive power over the shares. The filing also notes that the ownership includes warrants with conversion limitations that prevent the holders from beneficially owning more than 9.99% of the company's shares.